2026 ICD-10-CM Diagnosis Code C54.8Malignant neoplasm of overlapping sites of corpus uteri

ICD-10-CM CodesC00–D49C51-C58C54

ICD-10-CM C54.8
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C54.8 is a billable ICD-10-CM diagnosis code for malignant neoplasm of overlapping sites of corpus uteri. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 736 through 741, 754 through 756. Coders also document this condition as overlapping malignant neoplasm of body of uterus. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Female reproductive system cancers - uterus.

Code Identity

ICD-10-CM Code
C54.8
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of overlapping sites of corpus uteri
Short Description
Malignant neoplasm of overlapping sites of corpus uteri
Same as the full description in the CMS dataset.
Parent Code
Malignant neoplasm of corpus uteri

Code Classification

ChapterC00–D49Neoplasms
SectionC51-C58Malignant neoplasms of female genital organs
CategoryC54Malignant neoplasm of corpus uteri
This CodeC54.8Malignant neoplasm of overlapping sites of corpus uteri

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Overlapping malignant neoplasm of body of uterus
  • Overlapping malignant neoplasm of female genital organs

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO031
Female reproductive system cancers - uterus
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
corpus overlapping sitesC54.8
uterus, uteri, uterine overlapping sitesC54.8

Patient EducationClinical

Uterine Cancer

Uterine cancer is a cancer that forms in tissues of the uterus, which is sometimes called the womb. The uterus is the place where a fetus grows during pregnancy.

The full article covers:

  • What is uterine cancer?
  • Who is more likely to develop uterine cancer?
  • What are the symptoms of uterine cancer?
  • How is uterine cancer diagnosed?
  • What are the treatments for uterine cancer?
  • Can uterine cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C54.8 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
182.8 Mal neo body uterus NEC
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C54.8Overview

Is C54.8 (Malignant neoplasm of corpus uteri) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of overlapping sites of corpus uteri on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C54.8 group to?

When malignant neoplasm of overlapping sites of corpus uteri is the principal diagnosis on an inpatient stay, it groups to MS-DRG 736, 737, 738, 739, 740, 741, 754, 755, 756, with relative weights from 0.9605 to 3.5745 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C54.8?

Under the General Equivalence Mappings, malignant neoplasm of overlapping sites of corpus uteri converts to ICD-9-CM 182.8 (mal neo body uterus NEC). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.